Literature DB >> 14506006

Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Catherine Liu1, Henry F Chambers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14506006      PMCID： PMC201119          DOI： 10.1128/AAC.47.10.3040-3045.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  41 in total

1.  First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.

Authors:  S Trakulsomboon; S Danchaivijitr; Y Rongrungruang; C Dhiraputra; W Susaemgrat; T Ito; K Hiramatsu
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

2.  Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-10-11       Impact factor: 17.586

Review 3.  Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections.

Authors:  P A Moise; J J Schentag
Journal:  Int J Antimicrob Agents       Date:  2000-11       Impact factor: 5.283

4.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

5.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

6.  Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals.

Authors:  M E Reverdy; S Jarraud; S Bobin-Dubreux; E Burel; P Girardo; G Lina; F Vandenesch; J Etienne
Journal:  Clin Microbiol Infect       Date:  2001-05       Impact factor: 8.067

Review 7.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Authors:  K Hiramatsu
Journal:  Lancet Infect Dis       Date:  2001-10       Impact factor: 25.071

8.  Staphylococcus aureus resistant to vancomycin--United States, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-05       Impact factor: 17.586

Review 9.  Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus.

Authors:  F C Tenover; J W Biddle; M V Lancaster
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

10.  Vancomycin-intermediate Staphylococcus aureus in a home health-care patient.

Authors:  J C Hageman; D A Pegues; C Jepson; R L Bell; M Guinan; K W Ward; M D Cohen; J A Hindler; F C Tenover; S K McAllister; M E Kellum; S K Fridkin
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883
View more
  86 in total

1.  Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used.

Authors:  T R Anderegg; R N Jones; H S Sader
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

2.  National surveillance of methicillin-resistant Staphylococcus aureus in Belgian hospitals indicates rapid diversification of epidemic clones.

Authors:  Olivier Denis; Ariane Deplano; Claire Nonhoff; Raf De Ryck; Ricardo de Mendonça; Sylvianne Rottiers; Raymond Vanhoof; Marc J Struelens
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

3.  Foot Infections in Diabetic Patients.

Authors:  James S Tan
Journal:  Curr Infect Dis Rep       Date:  2004-10       Impact factor: 3.725

4.  Colonization with vancomycin-intermediate Staphylococcus aureus strains containing the vanA resistance gene in a tertiary-care center in north India.

Authors:  Tuhina Banerjee; Shampa Anupurba
Journal:  J Clin Microbiol       Date:  2012-02-15       Impact factor: 5.948

5.  Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans.

Authors:  Susan L Fink; Richard A Martinello; Sheldon M Campbell; Thomas S Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

6.  Antimicrobial susceptibilities of health care-associated and community-associated strains of methicillin-resistant Staphylococcus aureus from hospitalized patients in Canada, 1995 to 2008.

Authors:  Andrew E Simor; Lisa Louie; Christine Watt; Denise Gravel; Michael R Mulvey; Jennifer Campbell; Allison McGeer; Elizabeth Bryce; Mark Loeb; Anne Matlow
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

7.  Mycotic pseudoaneurysm by vancomycin-intermediate Staphylococcus aureus: a rare cause of persistent bacteraemia.

Authors:  Toufik Mahfood Haddad; Saraschandra Vallabhajosyula; Pranathi Rao Sundaragiri; Renuga Vivekanandan
Journal:  BMJ Case Rep       Date:  2015-04-01

8.  Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

9.  Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.

Authors:  Adriana Renzoni; Christine Barras; Patrice François; Yvan Charbonnier; Elzbieta Huggler; Christian Garzoni; William L Kelley; Paul Majcherczyk; Jacques Schrenzel; Daniel P Lew; Pierre Vaudaux
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

10.  Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid.

Authors:  M Souli; K Pontikis; Z Chryssouli; I Galani; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.